PSMA PET Imaging and Radioligand Therapy in mCRPC: Insights From VISION and TheraP Trials

Neal Shore, MD, FACS, discusses how the patient profile in the VISION trial, which involved progression on multiple therapies, reflects typical cases for Lutetium-177 treatment, emphasizing the crucial role of PSMA PET imaging in determining treatment suitability.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 7:14

Loaded: 2.26%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -7:14

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

• en (Main), selected

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Patient Case 1: A Sixty-Five-Year-Old Man With Prostate Cancer

Now Viewing

EP: 2.PSMA PET Imaging and Radioligand Therapy in mCRPC: Insights From VISION and TheraP Trials

EP: 3.Sequencing Treatment and Optimizing Care in mCRPC: Insights From VISION and TheraP Trials

EP: 4.Advancing Prostate Cancer Treatment With Lutetium 617 and PSMA PET Imaging

EP: 5.Treatment Considerations for PSMA-Positive mCRPC Patients

Related Videos

Treatment Considerations for PSMA-Positive mCRPC Patients

Advancing Prostate Cancer Treatment With Lutetium 617 and PSMA PET Imaging

Sequencing Treatment and Optimizing Care in mCRPC: Insights From VISION and TheraP Trials

Patient Case 1: A Sixty-Five-Year-Old Man With Prostate Cancer